Immuron Ltd Financials

IMRN

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2023 Currency USD FYE June

This page shows Immuron Ltd (IMRN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. All figures are derived from SEC filings (10-K and 10-Q reports).

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

N/A

EPS (Diluted)

N/A

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$4.8M

Immuron Ltd held $4.8M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

228M

Immuron Ltd had 228M shares outstanding in fiscal year 2024.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

N/A

IMRN Balance Sheet

Metric	FY24
Total Assets	$22.0M
Current Assets	$20.4M
Cash & Equivalents	$4.8M
Inventory	$840K
Accounts Receivable	$417K
Goodwill	N/A
Total Liabilities	$2.4M
Current Liabilities	$2.2M
Long-Term Debt	N/A
Total Equity	$19.6M
Retained Earnings	-$72.1M

Metric	Q2'24	Q4'23	Q2'23	Q2'20	Q4'19	Q2'19
Total Assets	$19.9M-9.6%	$22.0M-4.8%	$23.1M+175.9%	$8.4M-2.2%	$8.6M+11.2%	$7.7M
Current Assets	$18.9M-7.2%	$20.4M	N/A	$6.5M-3.3%	$6.7M	N/A
Cash & Equivalents	$15.2M+218.9%	$4.8M-74.2%	$18.5M+281.7%	$4.8M-5.5%	$5.1M+22.2%	$4.2M
Inventory	$1.6M+92.8%	$840K	N/A	$596K+9.4%	$544K	N/A
Accounts Receivable	$559K+34.0%	$417K	N/A	$779K-19.6%	$969K	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.4M-0.6%	$2.4M+29.1%	$1.8M+20.7%	$1.5M+25.7%	$1.2M+132.2%	$521K
Current Liabilities	$2.2M+0.2%	$2.2M	N/A	$1.5M+22.3%	$1.2M	N/A
Long-Term Debt	N/A	N/A	N/A	$61K	N/A	N/A
Total Equity	$17.5M-10.7%	$19.6M-7.7%	$21.3M+210.4%	$6.9M-6.8%	$7.4M+2.4%	$7.2M
Retained Earnings	-$74.1M-2.9%	-$72.1M	N/A	-$56.3M+1.0%	-$56.9M	N/A

IMRN Financial Ratios

Metric	FY24
Gross Margin	N/A
Operating Margin	N/A
Net Margin	N/A
Return on Equity	N/A
Return on Assets	N/A
Current Ratio	9.20
Debt-to-Equity	0.12
FCF Margin	N/A

Metric	Q2'24	Q4'23	Q2'23	Q2'20	Q4'19	Q2'19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	N/A	N/A	N/A	N/A	N/A
Current Ratio	8.52-0.7	9.20	N/A	4.42-1.2	5.59	N/A
Debt-to-Equity	0.13+0.0	0.12+0.0	0.09+0.1	0.01-0.2	0.16+0.1	0.07
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Xtl Biopharmaceu XTLB

$5.7M

Adaptimmune Therapeutics Plc ADAP

$14.6M

Biomx Inc PHGE

$23.9M

Phio Pharmaceuticals Corp PHIO

$14.9M

Aptorum Group Ltd APM

$7.5M

Frequently Asked Questions

What are Immuron Ltd's total assets?

Immuron Ltd (IMRN) had $22.0M in total assets as of fiscal year 2024, including both current and long-term assets.

How many shares does Immuron Ltd have outstanding?

Immuron Ltd (IMRN) had 228M shares outstanding as of fiscal year 2024.

What is Immuron Ltd's current ratio?

Immuron Ltd (IMRN) had a current ratio of 9.20 as of fiscal year 2024, which is generally considered healthy.

What is Immuron Ltd's debt-to-equity ratio?

Immuron Ltd (IMRN) had a debt-to-equity ratio of 0.12 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.